Full-Time

Scientist, Preclinical

Posted on 9/26/2025

Nanovation Therapeutics

Nanovation Therapeutics

11-50 employees

Develops lipid nanoparticle nucleic acid therapies

Compensation Overview

$73k - $91k/wk

+ Bonus eligibility

Vancouver, BC, Canada

In Person

Category
Lab & Research (3)
, ,
Requirements
  • PhD in Immunology, Pharmaceutical Sciences, or a Life Sciences discipline, and 5+ years of related scientific experience, or the equivalent education and experience.
  • Expert knowledge and experience in a broad range of preclinical methodologies including use of nanoparticles in experimental in vitro and in vivo systems, development of novel assays and methods to assess immunological responses, nanoparticle function, and assessment of nanoparticle efficacy and toxicity.
  • Demonstrated leadership in positively leading and mentoring team members.
  • Demonstrated success in the management of multiple research projects and budgets.
  • Actively developing a track record of innovation and contribution of novel ideas.
  • Strong organizational skills, time management, and ability to prioritize.
  • Strong communication skills both written and oral: Communicates with respectful, honest, open, and objective communication.
  • Strong Initiative: Proactively looks for opportunities for self, peers, and the company.
  • Innovative: Proactively learns, adapts and generates new ideas individually and as a team member.
  • Solution Oriented: Proactively looks for solutions and comes to the table with assessments and solutions for self, peers, and the company.
  • Flexibility: Proactively plans ahead and is open to a variety of options and embraces change.
  • Lifelong Learner: Continuous learning and sharing of knowledge. Being curiosity-driven; looks for and finds the answers, collaboratively.
Responsibilities
  • Mentors and executes in vivo research in support of our research goals and plans.
  • Independently designs, executes and troubleshoots preclinical activities in support of characterization and performance testing of pharmaceutical formulations in various preclinical settings.
  • Generates, analyzes, tabulates data and results, writes/reviews reports and provides recommendations.
  • Assists with downstream processing and analysis of in vivo samples for flow cytometry, interpretation of tissue images, and other immunological assays, as well as; DNA, RNA and protein extraction for luminescence/fluorescence measurements, qPCR, and other assays as needed.
  • Follows SOPs; generates and maintains thorough and accurate documentation.
  • Openly communicates challenges and proposes solutions.
  • Additional responsibilities, as required.
  • Leads and helps guide project teamwork.
  • Provides oversight and technical support to other project teams.
  • Prepares and executes multiple internal and external project plans.
  • Prepares and reviews study reports and technical presentations for internal use and for clients.
  • Proactively collaborates and interacts with partners, and other groups/departments on related projects to develop, characterize, and test formulations.
  • Proactively conducts relevant scientific literature searches.
  • Actively establishes new capabilities based on literature review.
  • Identifies novel research opportunities.
  • Assists in the writing of patent applications.
  • Develops patentable ideas.
  • Develops the scientific team through mentoring, supervising, and providing guidance on assigned projects.
  • Supports and encourages the personal and professional growth and development of team members.
Nanovation Therapeutics

Nanovation Therapeutics

View

NTx develops lipid nanoparticle (LNP) platforms to deliver nucleic acid therapies, including mRNA, to specific tissues. Its products are scalable, customizable LNP formulations usable across routes of administration, offered through partnerships, licensing, and direct sales to pharma companies and research institutions. The company differentiates itself with a next‑generation LNP platform and a global network of NanoVation GENErators hubs that foster international collaboration and rapid development. Its goal is to improve delivery efficiency, safety, and durability of genetic medicines to make more diseases manageable or curable.

Company Size

11-50

Company Stage

Grant

Total Funding

$300K

Headquarters

Vancouver, Canada

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Novo Nordisk partnership worth $600M licenses lcLNP™ for two lead programs.
  • Convergent Ventures funding expands board with Absci and Notch executives.
  • Life Sciences BC 'Deal of the Year' award validates lcLNP™ potential.

What critics are saying

  • Acuitas licenses superior LNPs to Intellia, eroding NanoVation's share.
  • Precision NanoSystems sues for IP infringement, freezing operations.
  • FDA clinical holds halt extrahepatic programs due to immune activation.

What makes Nanovation Therapeutics unique

  • NanoVation's lcLNP™ enables extrahepatic delivery for cardiometabolic diseases.
  • Spin-off from NMIN’s NanoCore with Dominik Witzigmann's LNP expertise.
  • Global NanoVation GENErators foster international collaboration hubs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Performance Bonus

Paid Vacation

Paid Sick Leave

Company Stock Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-10%

1 year growth

-8%

2 year growth

-8%
BIOTECanada
Jul 10th, 2025
NanoVation - Wins "Deal of the Year" award from Life Sciences BC

Biotech is thrilled to share that NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards!

Pulse 2.0
Dec 3rd, 2024
NanoVation Therapeutics Secures New Funding

NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million to develop genetic medicines. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson and David Main, bringing extensive biotech experience.

Postmedia Network
Nov 19th, 2024
NanoVation Therapeutics Secures Funding, Expands Board

NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson, CFO and CBO of Absci, and David Main, CEO of Notch Therapeutics, bringing expertise in biotech growth and strategic partnerships.

Business Wire
Nov 19th, 2024
NanoVation Therapeutics Announces Expansion of Board of Directors and Completion of Funding Round Led by Convergent Ventures

NanoVation Therapeutics announces expansion of Board of Directors and completion of funding round led by Convergent Ventures.

BioWorld
Sep 19th, 2024
Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases

Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases.

INACTIVE